The 'no-reflow' phenomenon after a percutaneous coronary intervention (PCI) in patients with acute ST-segment elevation myocardial infarction (STEMI) is a strong predictor of both short- and long-term mortality. Glucagon-like peptide-1 (GLP-1) exerts a cardioprotective effect during ischemia reperfusion injury. We planned to evaluate the effects of liraglutide on myocardial no-reflow after PCI for STEMI.A total of 284 patients with STEMI undergoing PCI were enrolled in this study between September 2013 and March 2015. Of these, 210 patients were randomized 1:1 to receive either liraglutide or placebo 30 min before PCI (1.8 mg).The primary end point, the prevalence of no-reflow, was significantly lower in the liraglutide group than in the control group (5

作者：Wei Ren, Chen；Feng, Tian；Yun Dai, Chen；Jing, Wang；Jun Jie, Yang；Zhi Feng, Wang；Jin, Da Wang；Qing Xiu, Ning

来源：International journal of cardiology 2016 年 208卷